

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai Henlius Biotech, Inc.**

**上海復宏漢霖生物技術股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 2696)**

## **VOLUNTARY ANNOUNCEMENT**

### **INCREASE IN SHAREHOLDING BY THE CONTROLLING SHAREHOLDER**

This announcement is made by Shanghai Henlius Biotech, Inc. (the “**Company**”) on a voluntary basis.

On 24 November 2020, the board of directors of the Company (the “**Board**”) were notified by Fosun Industrial Co., Limited (“**Fosun Industrial**”), a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“**Fosun Pharma**”), a controlling shareholder of the Company, that Fosun Industrial made on-market purchases on The Stock Exchange of Hong Kong Limited of an aggregate of 164,500 H Shares of the Company on 23 November 2020, upon the completion of which Fosun Pharma, through its wholly-owned subsidiaries indirectly controlled 297,109,887 Shares of the Company, representing approximately 54.67% of the total issued shares of the Company as at the date of this announcement. Fosun Industrial has also notified the Company that, depending on market conditions, it may continue to purchase H Shares of the Company through on-market purchases.

On Behalf of the Board  
**Shanghai Henlius Biotech, Inc.**  
**Qiyu CHEN**  
*Chairman*

Hong Kong, 24 November 2020

*As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the executive director, Mr. Qiyu Chen as the chairman and non-executive director, Mr. Yifang Wu, Ms. Xiaohui Guan, Dr. Aimin Hui and Mr. Zihou Yan as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Dr. Ruilin Song as the independent non-executive directors.*